Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial
Liang Wei, Joseph George(Birmingham Women’s and Children’s NHS Foundation Trust), Paul Ingravallo, Won Young Tak(Kyungpook National University Hospital), Emily Barr(University at Buffalo, State University of New York), Э З Бурневич, Rohit Talwani, Svetlana Kizhlo, D.Y. Kim, Cheng‐Yuan Peng(China Medical University), Tawesak Tanwandee(Siriraj Hospital), Jung Heo, К. В. Жданов, D. Zhongping, Lie-Xing Liang, Barbara J. Evans(University of Houston), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pin‐Nan Cheng(National Cheng Kung University Hospital), Vān Kính Nguyễn(Abbott Northwestern Hospital), I‐Shyan Sheen(Chang Gung University), George J. Hanna(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 10
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Federated learning for predicting clinical outcomes in patients with COVID-19
|Nature Medicine|2021|760